The number of patients requiring an internal fixation device or artificial joint has grown rapidly. In the United States alone, more than 4.4 million people have at least one internal fixation device and more than 1.3 million people have an artificial joint. Bacterial infection induced by an implant placement (
Clinical practice has shown that systemic antibiotics are unable to provide effective treatment for implant-associated infections. At the present time, only a high dose of antibiotics applied locally at the bone-implant interface can prevent such bacterial infections. However, this treatment causes a number of side effects, such as increased bacterial resistance to antibiotics, allergic reactions, and microbial flora depletion. Thus, it is often the best solution to remove the device, treat the infection, and repeat surgical introduction of a new device. This kind of procedure is costly, both financially and psychologically, as well as time-consuming.
Due to the rapid increase in use of artificial implants, it is critical that new strategies to prevent infection are developed, and in particular, antibacterial agents. One of the interesting options is the introduction of a non-antibiotic antimicrobial substance, for example, into the glue used during introduction of indwelling medical devices (Scheme 1 in
Silver has long been known to exhibit strong inhibitory and bactericidal effects as well as a broad spectrum of antibacterial properties. Since ancient times, people have known that water can remain suitable for drinking for a long time if stored in silver jars. Colloidal silver and silver nitrate have been used safely in burn therapy, urinary tract infections, and central venous catheter infections. The inhibitory effects of silver and silver compounds on bacteria is believed to be associated with silver reacting with microbial DNA or the sulfhydryl groups found in the enzymes of bacterial electron transport chains, causing its inactivation. One of the applications of silver and its compounds is reduction of postoperative infections caused by implants. Intrinsically low toxicity silver compounds have been loaded into several implant materials such as bioglass and bone cement, and the resulting material may be used for implant therapies in the health care industry. However, no silver(I) compounds have been reported which demonstrate combined light and thermal stability, chemical inertness, water insolubility, and antimicrobial activity. The main problems appear to be poor knowledge, insufficient development, and lack of subsequent studies of organic ligands to provide such properties.
The present disclosure advances the art by providing an anti-microbial material suitable for use in biomaterials and medical devices. In one embodiment, ten silver(I) cyanoximates of AgL composition (L=NC—C(NO)—R, where R is electron withdrawing groups: —CN, —C(O)NR2, —C(O)R′ (alkyl), —C(O)OEt, 2-heteroaryl fragments such as 2-pyridyl, 2-benzimidazolyl, 2-benzoxazolyl, 2-benzthiazolyl) have been synthesized and characterized using spectroscopic methods and X-ray analysis. Crystal structures of four complexes are disclosed which reveal the formation of two-dimensional (2D) coordination polymers of different complexity in which anions exhibit bridging or combined chelate and bridging binding modes. In another embodiment, anions are in the nitroso form in these compounds.
In one aspect, the disclosed AgL complexes are sparingly soluble in water and are thermally stable to a temperature as high as 150° C. The synthesized compounds disclosed herein demonstrate relatively high insensitivity toward visible light and UV-radiation, which may be explained based on their polymeric structures with multiple covalent bonds between bridging cyanoxime ligands and Ag(I) centers. All ten silver(I) cyanoximates are tested in vitro on the subject of their antimicrobial activity against both Gram-positive and Gram-negative microorganisms such as Escherichia coli, Klebsiella pneumoniae, Proteus sp., Pseudomonas aeruginosa, Enterococcus hirae, Streptococcus mutans, Staphylococcus aureus, and Mycobacterium fortuitum as well as against Candida albicans in solutions, and in the solid state as pressed pellets and dried filter paper disks presoaked with solutions of AgL in DMF. Results showed pronounced antimicrobial activity for these complexes.
In one embodiment, the combination of at least the following five factors allows for the use of silver(I) cyanoximates in biomaterials and medical applications: (1) light insensitivity, (2) poor water solubility, (3) high thermal stability, (4) lack of toxicity of organic ligands, and (5) in vitro antimicrobial activity. In one aspect, the disclosed compounds may be included as antimicrobial additives to acrylate glue. In another aspect, the disclosed compounds may be cured by UV-radiation, and may be used in introduction of prosthetic joints and dental implants. In another aspect, the disclosed compounds may also be used for the prevention of biofilm formation on several types of indwelling medical devices.
One particular class of low molecular weight organic compounds can act as ligands for binding silver(I) cations and form complexes that may satisfy all the specific requirements outlined above. The disclosed compounds are species of a class of compounds known as oximes, which represent versatile organic molecules that have been extensively used as excellent ligands in analytical, inorganic, and bioinorganic chemistry. Furthermore, among oximes one specific group of substances called cyanoximes—compounds with the general formula HO—N═C(CN)—R— represents a new, special class of biologically active molecules that are also capable of binding to different metal ions.
In one embodiment, the presence of the CN-group in these compounds significantly increases their acidity and makes them better ligands for binding metal ions as compared to conventional monoximes. Earlier data showed no intrinsic in vitro cytotoxicity of free organic cyanoximes. Here, it is shown that silver(I) cyanoximates are insoluble in water, represent thermally and chemically stable compounds, and exhibit antimicrobial activity. With the exception of several publications and presentations, no systematic studies have been reported regarding light-stable silver(I) antimicrobial compounds targeting specific infections, and no oxime-based compounds have been tested on that matter at all.
In this disclosure, results relating to systematic investigation of the synthesis, spectroscopic, structural and photophysical characterization, for a new group of light-insensitive silver(I) cyanoximates are shown. This new group of light-insensitive silver(I) cyanoximates is primarily based on ligands shown in Scheme 2 in
Light insensitive and stable compounds possessing desirable anti-microbial properties are disclosed. The compounds may be suitable for use in biomaterials and medical devices.
By way of example, ten silver(I) cyanoximates were synthesized and characterized using elemental analyses, spectroscopic methods, and X-ray analysis. Five complexes were obtained and characterized for the first time, while crystal structures were determined for four compounds. All synthesized Ag(I) complexes have demonstrated thermal stability upon heating up to 150° C. and a remarkable light insensitivity. That includes years of exposure to daylight or hours of direct exposure to the short wavelength (254 nm) UV-radiation. The antimicrobial activity of all obtained silver(I) cyanoximates was tested both in solutions and in the solid state against Escherichia coli, Klebsiella pneumoniae, Proteus sp., Pseudomonas aeruginosa, Enterococcus hirae, Streptococcus mutans, Staphylococcus aureus, Mycobacterium fortuitum, Candida albicans, and in addition on several multidrug-resistant bacterial strains isolated from patients with nosocomial infections K. pneumoniae 244, P. aeruginosa, Streptococcus pneumoniae PCI, AMA, Enterococcus faecium VRE (vancomycin-resistant), S. aureus MRSA (methicillin-resistant). Examination of fresh clinical isolates from nosocomial infections revealed the data valuable for application purposes of the investigated compounds. Results have indicated pronounced antimicrobial activity of studied complexes.
A combination of four properties including (1) thermal stability, (2) light insensitivity, (3) poor water solubility, and (4) antimicrobial activity is important for their intended potential applications in indwelling medical devices. Thus, visible light insensitive silver(I) complexes with anti-microbial activity will offer benefits as an adjunct or alternative material compared to current materials used for implants. Inertness of these metal compounds toward intense UV-light allows their application as additives to UV-radiation curable polymeric glues in joint replacement therapy and dental implant insertions. Because bacterial adhesion and biofilm formation are important predisposing factors in the development of clinical implant infection, it is crucial that silver(I) cyanoximates showed an effect on their development. A significant thermal resistance of these complexes is essential for equipment sterilization, while poor water solubility will prevent compounds from leaching out from solidified polymeric composites, or from the surface of indwelling devises. Silver(I) complexes introduced in polymeric acrylate glue composites will prevent infection from occurring.
The silver(I) cyanoximates may be added to conventional acrylate-based light-curable glues used in medical practice during introduction of indwelling devices. Light-induced bulk polymerization may be conducted. Samples for these materials may be in the form of disks or small cylinders in order to model conditions and shapes for indwelling medical devices. Mixtures of silver(I) cyanoximates may also be tested to ensure broader microbicidal activity. Because preliminary experiments demonstrated that Ag(I) cyanoximates inhibit microbial growth in liquid and solid media, these complexes may prevent or inhibit bacterial adhesion and biofilm formation. Thus, the effect of Ag(I) complexes on adhesion of P. aeruginosa, S. aureus, and S. mutans may be tested. The inability of bacteria to develop biofilm on the coated surfaces made with the disclosed compounds may be utilized to achieve the anti-microbial objective.
In one embodiment, methods are disclosed for treating indwelling medical devices to eliminate microbes which comprise the steps of applying a water-insoluble silver cyanoximate to the surface of the indwelling medical device prior to or during the introduction of the indwelling medical device into a patient.
In another embodiment, the silver cyanoximate may be selected from the group consisting of: 2-(Oximido)-2-benzoxazoleacetonitrile Silver(I), Ag(BOCO); Silver(I) Nitrosodicyanomethanide, Ag(CCO); Silver(I) α-Oximido-(acetamide)acetonitrile, Ag(ACO); Silver(I) α-Oximido-([N,N-dimethylamine]acetamide)acetonitrile, Ag(DCO); Silver(I) α-Oximido-(ethylacetoxy)acetonitrile, Ag(ECO); Silver(I) α-Oximido-(2-pivaloyl)acetonitrile, Ag(PiCO); Silver(I) α-Oximido-(2-benzoyl)acetonitrile, Ag(BCO); Silver(I) α-Oximido-(2-pyridyl)acetonitrile, Ag(2PCO); Silver(I) α-Oximido-(2-[N-methyl]benzoimidazolyl)acetonitrile, Ag(BIMCO); Silver(I) α-Oximido-(2-benzothiazolyl)acetonitrile, Ag(BTCO).
In another embodiment, an antimicrobial additive is disclosed which may be added to acrylate glue for securing an indwelling medical device, wherein the additive comprises at least one silver cyanoximate. In one aspect, the additive may contain a silver cyanoximate selected from the group consisting of: 2-(Oximido)-2-benzoxazoleacetonitrile Silver(I), Ag(BOCO); Silver(I) Nitrosodicyanomethanide, Ag(CCO); Silver(I) α-Oximido-(acetamide)acetonitrile, Ag(ACO); Silver(I) α-Oximido-([N,N-dimethylamine]acetamide)acetonitrile, Ag(DCO); Silver(I) α-Oximido-(ethylacetoxy)acetonitrile, Ag(ECO); Silver(I) α-Oximido-(2-pivaloyl)acetonitrile, Ag(PiCO); Silver(I) α-Oximido-(2-benzoyl)acetonitrile, Ag(BCO); Silver(I) α-Oximido-(2-pyridyl)acetonitrile, Ag(2PCO); Silver(I) α-Oximido-(2-[N-methyl]benzoimidazolyl)acetonitrile, Ag(BIMCO); Silver(I) α-Oximido-(2-benzothiazolyl)acetonitrile, Ag(BTCO).
It is to be recognized that silver(I) cyanoximates compounds other than the ones synthesized and disclosed may possess similar properties as the compounds that are described in details in the present disclosure.
The following examples illustrate the present disclosure. These examples are provided for purposes of illustration only and are not intended to be limiting. The chemicals and other ingredients are presented as typical components or reactants, and various modifications may be derived in view of the foregoing disclosure within the scope of the invention.
This Example details some of the material, methods, and instruments employed in this disclosure.
Materials and Physical Measurements. Reagent or analytical grade materials were obtained from commercial suppliers (Aldrich and Mallinckrodt) and were used without further purification. Elemental analyses on C, N, H content were performed by a combustion method at the Atlantic Microlab (Norcross, Ga.). Melting points for organic ligands were determined using the UniMelt apparatus (by Thomas-Hoover) without correction. Identification of the obtained organic compounds was carried out using 1H, 13C NMR spectroscopy (Varian INova 400; T=296 K; in DMSO-d6, with TMS as an internal standard TMS, by Cambridge Laboratories), and mass-spectrometry (positive FAB technique for the macrocyclic compound 14-ane[N4]; m-nitrobenzylic alcohol, NBA, as a matrix using Autospec Q and ZAB spectrometers from Manchester, UK). IR spectra for synthesized organic cyanoxime ligands were recorded in KBr pellets (400-4000 cm−1 region at 4 cm−1 resolution) using a Nicolet Impact 410 spectrophotometer operating with OMNIC software. At the same time, IR spectra of silver(I) complexes were obtained from mulls in Nujol between two 2 cm KBr disks. Visible spectra for the suspensions of several Ag(I) cyanoximates in mineral oil between two quartz plates 4×1 cm were recorded on an Agilent HP 8453E spectrophotometer in the range of 300-1100 nm at 293 K. Room temperature solid-state diffusion reflectance spectra of Ag(ACO) and Ag(PiCO) were obtained on a Varian Bio-100 spectrophotometer with an integrating sphere and MgO as a standard. Electrical conductivity of 1 mM solutions of synthesized silver(I) cyanoximates in anhydrous DMSO was measured at 296 K using a YSI Conductance-Resistance meter model 34. Solutions of ammonium bromide, tetrabutyl-ammonium bromide, and tetraphenyl-phosphonium bromide (as 1:1 electrolytes), and hydrazinium dichloride (as 1:2 electrolyte) were used for the electrode calibration.
X-ray Crystallography. Suitable crystals of compounds Ag(ACO), Ag(DCO), Ag(PiCO), and Ag(ECO) were mounted on a thin glass fiber on the goniometer head of a Bruker APEX 2 diffractometer equipped with a SMART CCD area detector. All data sets were collected at low temperature. The intensity data for suitable crystals of these compounds were collected in ω scan mode using Mo tube (Kα radiation; λ=0.71073 {acute over (Å)}) with a highly oriented graphite monochromator. Intensities were integrated from four series of 364 exposures, each covering 0.5° in ω within 20 to 60 s of acquisition time and the total data set being a sphere. The space group determination was done with the aid of XPREP software. Absorption corrections were applied based on crystal face indexing obtained using actual images recorded by video camera. The following data processing was performed using the SADABS program that was included in the Bruker AXS software package. The structures were solved by direct methods and refined by least-squares on weighted F2 values for all reflections using the SHELXTL program. All atoms received assigned anisotropic displacement parameters and were refined without positional constraints. All nine hydrogen atoms in the structure of Ag(PiCO) were found on the difference map and their positions were refined as well. Crystals of Ag(ACO) turned out to be multidomain species. Complex Ag(DCO) contained a disordered solvent molecule with partial occupancy. A complete set of bonds and angles around metal centers is presented in
Synthesis of Compounds. Preparation of cyanoximes and their Ag(I) complexes is depicted in Scheme 3 in
2-(Oximido)-2-benzoxazoleacetonitrile Silver(I), Ag(BOCO). Brown H(BOCO) in the amount of 0.4605 g (2.46 mM) of brown H(BOCO) was dissolved in a mixture of 10 mL of EtOH, diluted with 10 mL of water, heated to +50° C., and then added dropwise to a solution of 0.169 g (1.22 mM) of K2CO3 in 10 mL of H2O. The reaction mixture turned immediately very dark brown and was placed for 2 min into an ultrasound bath to accelerate the evolution of CO2. A solution of 0.4183 g (2.46 mM) of AgNO3 in 10 mL of water was added dropwise under intensive stirring to a solution of K(BOCO) above. Mixing resulted in a very fine orange-brown precipitate, which after an additional 20 min of stirring was filtered, washed with three portions of 10 mL of water, and then dried in a vacuum desiccator charged with H2SO4 (c) for 3 days. The yield of orange-brown Ag(BOCO) was 98% (0.701 g). Anal. Calc. for C9H4AgN3O2 (Found) %: C, 36.77 (37.12); H, 1.37 (1.58); N, 14.49 (14.33). Other silver(I) cyanoximates follow.
Silver(I) Nitrosodicyanomethanide, Ag(CCO). Bright-yellow powder; yield 96%, complex decomposes in the range of 190-209° C. Anal. Calc. for C3N3OAg (Found) %: C, 17.84 (17.98); N, 20.81 (20.69).
Silver(I) α-Oximido-(acetamide)acetonitrile, Ag(ACO). As shown in
Silver(I) α-Oximido-([N,N-dimethylamine]acetamide)acetonitrile, Ag(DCO).0.5MeOH. As shown in
Silver(I) α-Oximido-(ethylacetoxy)acetonitrile, Ag(ECO). As shown in
Silver(I) α-Oximido-(2-pivaloyl)acetonitrile, Ag(PiCO). As shown in
Silver(I) α-Oximido-(2-benzoyl)acetonitrile, Ag(BCO). Purple fine powder obtained with yield 71%; decomposition at 180-182° C. Anal. Calc for C9H5AgN2O2 (Found): C, 38.47 (38.29); H, 1.79 (1.92); N, 9.97 (9.86).
Silver(I) α-Oximido-(2-pyridyl)acetonitrile, Ag(2PCO). Yellow powder, yield 87%; decomposition at 178-187° C. Anal. Calc for C7H5N3O (Found): C, 33.10 (34.83); H, 1.59 (1.90); N, 16.54 (17.18).
Silver(I) α-Oximido-(2-[N-methyl]benzoimidazolyl)acetonitrile, Ag(BIMCO).0.5H2O. The compound represents a very fine yellow-green powder, decomposes at 160-180° C.; yield 96%. Anal. Calc for C10H8AgN4O15 (Found): C, 37.97 (37.60); H, 3.16 (2.47); N, 17.72 (17.20).
Silver(I) α-Oximido-(2-benzothiazolyl)acetonitrile, Ag(BTCO).1.5H2O. Orange-brown fine powder; yield 100%; at ˜214-219° C. complex decomposes. Anal. Calc for C9H7N3O2SAg, %: C, 32.03 (32.18); H, 2.08 (2.31), N, 12.46 (12.86).
All synthesized Ag(I) cyanoximates are sparingly soluble in water, but dissolve in donor solvents such as pyridine, 2-picoline, and DMSO.
Photophysical Measurements. Light sensitivity and stability of synthesized Ag(I) cyanoximates was studied at 296 K using a low-pressure Hg lamp with >85% output at λmax=254 nm where the intensity of light was measured with a UVX radiometer (UK). After 4 min warm-up time, this lamp generated a steady flux of UV-radiation that was equal to the dose of 10.13 J/cm2 within 30 min. Prior to these investigations, complexes were thoroughly dried under high vacuum (<10−4 Torr) and ground into a powder using an agate mortar. This made it easy to apply these compounds to paper, adhesive tape, or cardboard. Samples of complex were spread on white cardboard with an exposed circular area (via a mask) of ˜3 cm. The radiation source was positioned 1 cm from the sample. A pristine white silver chloride prepared in the dark was used as a control substance to access the light stability of silver(I) cyanoximates. Digital pictures of irradiated samples were taken every 30 min using a stationary digital camera (Kodak DX7630; 6.1 Mpx), and native images were cropped to square shape without any contrast or brightness editing using Samsung Digimax Viewer 2.0 software.
Antimicrobial Activity Studies. Bacterial Strains and Growing Conditions. The strains of bacteria were obtained from Polish Collection of Microorganisms (PCM) of the Institute of Immunology and Experimental Therapy of Polish Academy of Sciences and were used throughout this study. Both Gram-negative and Gram-positive bacteria, as well as yeasts, commonly isolated from patients suffering implant-related infections, were chosen for experiments. They included Escherichia coli PCM 1144 (ATCC #10536), Klebsiella pneumoniae PCM 57, Proteus sp. PCM 542 (ATCC #13315), Pseudomonas aeruginosa PCM 2563 (ATCC #15442), Streptococcus mutans PCM 2502, Staphylococcus aureus PCM 2602 (ATCC #6538), Enterococcus hirae PCM 2559 (ATCC #10541), Mycobacterium fortuitum PCM 672, Candida albicans PCM 2566 (ATCC #10231). In addition, several multidrug-resistant bacterial strains isolated from patients with nosocomial infections K. pneumoniae 244, P. aeruginosa 2314, AMA, Enterococcus faecium VRE (vancomycin-resistant), Streptococcus pneumoniae PCI, S. aureus MRSA (methicillin-resistant), S. aureus MRSC (coagulase-negative methicillin-resistant), were also included in the in vitro testing. Bacteria were cultivated on sugar broth at 37° C. for 24 h in aerobic conditions, and prior to use in tests, cells were diluted with the same medium to obtain suspensions of about 2×105 cfu/mL.
Antibacterial Tests in Solutions. The antibacterial activities of synthesized Ag(I) cyanoximates were determined against bacterial strains by the microplate Alamar Blue assay. Stock solutions of AgL compounds were prepared in DMSO (1 mg/mL) and then were diluted with appropriate media in the range from 0.03 to 1000 μg/mL on the cell culture microtitration plate. Aliquots of 100 μL of the studied AgL compound at different concentrations and 100 μL of the diluted suspension of the bacterial cells were added to wells. Control wells contained either bacteria only or medium only, and plates were incubated at 37° C. for 48 h. After that, solutions of 20 μL of Alamar Blue reagent (AbD Serotec) (10×diluted) and 12.5 μL of 20% Tween 80 were added to wells and incubation was continued at 37° C. for 2 more hours. The fluorescence was measured using Victor2 apparatus (Wallac, Perkin-Elmer), and the experiment was repeated three times. The minimal inhibitory concentration (MIC) was defined as the lowest drug concentration which prevented a color change from blue to pink, inhibiting the bacterial growth for ≧90%. Means and standard error values were determined using the Microsoft Excel.
Antibacterial Tests in Solid State: Soaked Dried Paper Disks and Pellets. Solutions (or suspensions if the compound was not completely solubilized) of studied Ag(I) cyanoximates in DMF at 10 mg/mL concentration were prepared and 20 μL of it was placed on filter paper discs (diameter 12 mm). These discs were dried for ˜2 h in the dark prior to testing where each filter was placed on agar plates with inoculated microorganisms, which were then incubated at 37° C. for 24 h. Thereafter, microorganisms' growth inhibition zone (if present) was measured (in mm).
Also, Ag(I) cyanoximates were pressed into 12 mm in diameter pellets using a Carver 20 tons hydraulic press. The method of testing pellets was similar to the one described above. Solid pellets of AgL were carefully placed on agar plates with inoculated bacteria. The exposition time was 24 h at 37° C., after which inhibition zones were measured and results were documented by digital photography.
Ten light insensitive silver(I) cyanoxime complexes (or compounds) with ligands shown in Scheme 2 (
Chemical Part: Synthesis and Characterization of Ligands and Metal Complexes. A methodology for a high-yield preparation of cyanoximes from substituted acetonitriles has been developed and is disclosed herein. The R—CH2—CN compounds are mostly commercially available pure substances which can be converted in a one-step procedure to respective cyanoximes (Scheme 3 in
Identification and characterization of the obtained and purified organic molecules were carried out using elemental analyses, thin-layer chromatography (TLC), and spectroscopic methods such as UV-visible, IR, 1H, 13C NMR spectroscopy (including 2D COSY, HMQC, and HSQC experiments). Ligands shown in Scheme 2 have the ability to form chelate complexes and also act as bridging ligands. They possess interesting features—electronic and structural—that are reflected in their hydrophilic/hydrophobic character and acidity (ligands 1-6, Scheme 2), the ability to form layered structures in the solid state due to π-π stacking interactions between heterocyclic groups (ligands 7-10, Scheme 2), and, finally, multiple donor centers capable of tightly binding silver(I) atoms to form coordination polymers of different complexity. Coordination compounds of the latter metal are particularly interesting: they have unusual structures, show properties of gas-sensing materials, and lately demonstrate antimicrobial activity. These aforementioned electronic and structural factors allow the fine-tuning of properties of the obtained Ag(I) complexes and possibility for study of structure-activity relationships during investigations of their in vitro biological activity.
Silver(I) cyanoximates with ligands shown in Scheme 2 have 1:1 stiochiometry and are poorly soluble in aqueous/alcohol solutions and thus can be conveniently separated from the reaction mixture. These AgL complexes are also insoluble in hydrocarbons, acetone, but are sparingly soluble in CH3CN. Dry, solid Ag(I) cyanoximates have shown significant thermal stability and do not decompose upon heating to 150° C.
Visible spectra of fine suspensions of studied Ag(I) cyanoximates in mineral oil revealed broad ligand-based single band in the range of 400-500 nm that corresponds to π→π* transition in the nitroso chromophore. Obtained data of electron spectroscopy allowed estimation of the band gap in AgL, which turned out to be in the range of 3.00-3.55 eV. What is the most important for current studies is that all synthesized AgL are light insensitive as was shown after many years of their exposure to daylight without change (
Crystal Structures. Details of determined crystal structures of Ag(ACO), Ag(DCO), Ag(PiCO), and Ag(ECO) are shown in
Ag(ACO). This complex represents layered 2D coordination polymer in which cyanoxime anion acts as both a chelating ligand and a bridging group utilizing oxygen atoms of the amide and nitroso groups (
Ag(DCO). This complex also represents a 2D layered coordination polymer (
Ag(PiCO). The crystal structure of this compound is a layered 2D coordination polymer as well (
Ag(ECO). This is the first known structure containing this cyanoxime ligand. The crystal structure of this complex follows already described Ag(DCO) and Ag(PiCO) and also represents layered 2D coordination polymer (
Determined single crystal structures of silver(I) cyanoximates described here silver(I) cyanoximates truly reflect structures of bulk materials since their calculated and experimental powder XRD patterns are in a good agreement.
Photophysical Part: UV-Light Stability Studies. Silver(I) cyanoximates with chelating ligands shown in Scheme 2 exhibited a remarkable visible light insensitivity for years of direct exposure to daylight (
After many hours of intense short-wavelength UV-radiation powdery samples of Ag-cyanoximates eventually become darkened. It should be noted that for the purpose of intended application of synthesized compounds—as antimicrobial light-insensitive additives to adhesives for indwelling medical devices—only minutes of light stability are required. The source of a dark color in final products of degradation is metallic silver that is in the colloidal state. This conclusion is based on comparative analysis of the XRD patterns of fine metallic silver powder (obtained from substitution reaction between A1 wire and AgNO3 aqueous solution at 293 K, pH=6.0) and those for the initial Ag-cyanoximates, and same complexes darkened after UV-light exposure. Thus, no lines corresponding to metal Ag were observed in the Θ-2Θ XRD scans. This is attributed to two factors: (1) to the small size of silver particles estimated to be less than ˜100 {acute over (Å)}, and (2) small physical quantity of produced metallic silver. A typical sample mass of initial AgL spread over the cardboard used in the UV-irradiation studies did not exceed 40-50 mg However, characteristic peaks of “plasmon” bands of colloidal silver at 380-450 nm were detected in UV-visible spectra of exposed Ag-cyanoximates in DMSO or Py in addition to the Tyndall effect. Both these features showed colloidal state of metal present in UV-light exposed samples.
Biological Part: In Vitro Assessment of Antibacterial Activity of Silver(I)-cyanoximates. Studies in Solutions. All 10 cyanoximates exhibited antimicrobial activity against the tested infection agents. The lowest MIC value was detected for Ag(DCO) and Ag(PICO), which indicated their highest activity. These data suggested that hydrophobic methylated cyanoximes ( ) showed stronger inhibitory effect possibly due to their interactions with cell membranes which may help in complexes' intracellular uptake. However, the solubility of silver(I) cyanoximates in DMSO and DMF is limited, and, therefore, there was a need in conducting experiments with solid samples of synthesized AgL. This was achieved by using dried paper disks presoaked with AgL solution. Seven out of 10 compounds were studied in this manner. Investigated compounds soluble in DMF were remarkably more effective against clinical isolates from nosocomial infections than to strains from the Collection of Microorganisms.
Solid State Studies. Seven cyanoximates (Ag(BCO), Ag(CCO), Ag(DCO), Ag(ECO), Ag(BIMCO), Ag(BOCO), and Ag(PiCO)) were deposited on filter papers and tested for their effect on bacterial growth on solid media. The inhibition zones of microbial growth was examined. The results demonstrated that studied Ag(I) cyanoximates exhibit antimicrobial activity in the solid state as well, but their efficiency was strain dependent. Furthermore, we tested the antimicrobial effect of the silver(I) cyanoximates deposited as pressed pellets (12 mm in diameter) against five strains of microorganisms grown on agar plates.
Changes may be made in the above compositions and methods without departing from the scope hereof. It should thus be noted that the matter contained in the above description should be interpreted as illustrative and not in a limiting sense.
Gerasimchuk N., et al., Inorg. Chem. 49:9863-74 (2010).
This application claims priority to U.S. Patent application 61/533,604 filed Sep. 12, 2011, the entire content of which is hereby incorporated by reference into this application.
Number | Date | Country | |
---|---|---|---|
61533604 | Sep 2011 | US |